Outlook Therapeutics (NASDAQ:OTLK) lost ~81% in the premarket on Wednesday after the company announced that a clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback